On December 23, Guangyao Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) biomedicine and health R & D and sales headquarters, which lasted two years, was successfully capped. With a total investment of 1.1 billion yuan, the project mainly constructs R & D center, biomedical incubator and mass entrepreneurship and innovation base. It is one of the key biomedical projects in Guangzhou.
The headquarters is also an important measure for the development of Guangzhou Pharmaceutical Group in the post world top 500 era. Li Chuyuan, Secretary of the Party committee and chairman of Guangzhou Pharmaceutical Group, said that after the completion of the headquarters, it will further expand the group’s industrial development space, improve its independent R & D strength, product competitiveness and resource integration, and help build a biomedical highland and a strong biomedical province and city in Guangdong, Hong Kong and Macao.
At the scene, Liu Changxiao, academician of the Chinese Academy of engineering, delivered a speech through video. The master of national medicine, Shi Guowei, Liang Huqing, Secretary of the Party committee and chairman of Guangzhou Construction Group, Guangzhou Kingmed Diagnostics Group Co.Ltd(603882) Secretary of the Party committee and chairman of the board, Liang Yaoming, attended the event.
The construction of Guangzhou Pharmaceutical Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) biomedical and health R & D and sales headquarters was started in 2019. Through the mode of “government guidance, enterprise first, market operation and policy promotion”, the headquarters project takes advantage of the industrial agglomeration advantages of Guangzhou International Biological Island, combined with the strong strength of Guangzhou Pharmaceutical group and high-quality biomedical research supporting services, Plan the development of biotechnology strategic emerging industries, incubator operation and innovation system from a global perspective, accelerate the scientific and technological innovation, promotion and application of key technologies in the economic development of the pharmaceutical industry, and form a new model of “international advanced technology – Chinese patent – Chinese industry – going global”.
The project covers an area of 31000 square meters, with a total construction area of 118000 square meters and a total investment of 1.1 billion yuan. It mainly constructs R & D centers, biomedical incubators and mass entrepreneurship and innovation bases, including biomedicine, traditional Chinese medicine and natural drugs, chemical innovative drugs and generic drugs research laboratories, physicochemical and testing centers, and carries out mass health products and biomedicine The R & D and application of innovative drugs such as small molecule drugs is a key construction project integrating innovative drugs and medical device R & D platform, R & D center, international pharmaceutical cooperation and exchange center, science and technology incubator and mass entrepreneurship and innovation base.
“The construction of Guangyao Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) R & D and sales headquarters is an important work to implement the made in China 2025 and build a biomedical highland in Guangdong, Hong Kong and Macao Li Chuyuan said that the design theme of the project is “fish leaping to the dragon’s gate and fish mouth holding beads”, which highlights that Guangyao group is in the development stage of “fish leaping to the dragon’s gate” after entering the world 500 list.
“Guangzhou Pharmaceutical Group has made major breakthroughs in scientific research platform echelon construction, talent training, major project research, industry university research cooperation and so on.” In his speech, he Guowei, a master of national medicine, said that he hoped that in the future, the group would make full use of the characteristic advantages of Guangzhou International Biological Island, strengthen international cooperation, strive to build a professional R & D platform with international influence and China’s first-class, and provide incubators, engines and accelerators for the biomedical industry in Dawan district.
It is reported that in the future, the group will take the industry as the link to strengthen the linkage and coordination between the science and technology resources of Biological Island and Macao’s science and technology, industry and international resources. The R & D and sales headquarters of Guangyao Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) will rely on the Biological Island innovation platform to accelerate the scientific and technological innovation and promotion application of the pharmaceutical industry, introduce, incubate or cultivate high-end products with independent intellectual property rights and competitiveness, Build a world-class innovation source, service area and incubator.
(South plus)
